Quiz
Test of Nuclear Medicine- Oncology 5th Year PMU
Questions in this quiz (50)
1Which are the main goals of nuclear oncology
- AImaging of the functional activity and the degree of proliferation of the tumor
- BThe degree of malignant tumor spread: lymphogenic and haematogenic
- CImaging and quantitative assessment of the effect from chemo- and hormone-therapy
- DAll answers are correct
2The scanning systems used in nuclear medicine are based on the principle of
- AEmission of Gamma-rays from the scanning system
- BTransition of Roentgen-rays through the patient's body
- CDetection of Gamma-rays or positron emission (pairs of annihilation Gamma-rays) emitted from the studied object
- DAll answers are correct
3Which methods of nuclear medicine are used for diagnosis of malignant tumours
- APET/CT
- BGamma camera scintigraphy
- CRadioimmunoassay of tumour markers
- DAll answers are correct
4Nuclear medicine diagnosis provides
- AMetabolic imaging
- BQuantitative assessment of physiological processes in the human body
- CTargeted planning of radiotherapy
- DAll answers are correct
5Nuclear medicine applies
- AUnsealed radioactive sources for medical diagnosis
- BUnsealed radioactive sources for radiotherapy
- CSealed radioactive sources for medical diagnosis and therapy
- DCorrect answers- a) and b)
6PET/CT is a multimodality system combining
- APET scanner with low-dose CT for improvement of the quality and precise localization of the functional image
- BPET scanner with possibility for additional targeted diagnostic contrast CT
- CAcquisition and fusion of functional and structural-anatomic images
- DAll answers are correct
7CT and PET scans demonstrate different aspects of disease indicating regions with
- AAltered metabolism (PET) and areas of structural change (CT)
- BAltered metabolism (CT) and areas of structural change (PET)
- CAltered metabolism (PET) and areas of structural change (PET)
- DAltered metabolism (CT) and areas of structural change (CT)
8Which of the following diagnostic methods belong to modern Nuclear medicine
- APET/CT
- BSPECT/CT
- CPET/MRI
- DAll answers are correct
9Which radionuclides are used for metabolic brachytherapy
- AHigh-energy γ (Gamma) emitters
- Bβ- (Beta)-emitters
- Cβ- (Beta) and γ (Gamma)-emitters
- DCorrect answers — b) and c)
10Nuclear medicine methods are used for
- ADiagnosis of benign and malignant diseases
- BTreatment of benign diseases
- CTreatment of malignant diseases
- DAll answers are correct
11PET /CT imaging has demonstrated significant application in the following clinical areas EXCEPT
- AOncology
- BCardiology
- CPulmonology
- DNeurology
12Which radiopharmaceuticals are used for tumor-specific imaging
- A131 I- NaI
- BIII In-Octreoscan
- C99m Tc-Tetrofosmin
- DAll answers are correct
13Malignant tumors present on scintigraphy with tumor-specific radiopharmaceuticals as
- AZones of increased uptake of the radiopharmaceuticals
- BZones of decreased uptake of the radiopharmaceuticals
- CZones of absent uptake of the radiopharmaceuticals
- DZones of normal uptake of the radiopharmaceuticals
14The most frequently used radiopharmaceutical for PET/CT imaging is
- A18F-FDG
- B99mTc-Pertechnetate
- C131-Iodine — Nal
- DNo correct answer
15The PET scanner is detector of
- AAlfa-particles
- BBeta-particles
- CPairs of annihilation Gamma rays
- DAll answers are correct
16Bone scintigraphy is
- AHighly specific diagnostic method
- BHighly sensitive diagnostic method
- CHighly sensitive and highly specific diagnostic method
- DNon-sensitive and non-specific diagnostic method
17The main indication for bone scintigraphy is
- AInflammatory bore disorders
- BEarly detection of bone metastases
- CBenign bone tumors
- DDegenerative joint disorders
18Metabolic brachytherapy with Metastron (89 Stroncium) is applied in patients with
- ABone metastases
- BPulmonary metastases
- CBrain metastases
- DLiver metastases
19Contraindication for metabolic brachytherapy in patients with metastatic bone disease is
- AAdvanced stage of the disease
- BConsiderable myelo-depression
- CInflammatory conditions
- DAll answers are correct
20Differentiated Thyroid cancer after total thyroidectomy and manifested distant haematogenic metastases is treated successfully with
- AOperation
- BRadioiodine metabolic brachytherapy
- CChemotherapy
- DElectron therapy
21Which of the following statements describing 18-F FDG PET imaging in thyroid carcinoma is FALSE
- A18-F FDG PET can be negative in well differentiated types
- B18-F FDG PET negative lesions are more likely to be resistant to 1-131 treatment
- C18-F FDG uptake is proportional to Iodine uptake
- D18-F FDG PET may not be accurate in patient with Tg levels below 2 ng/ dL
22The most specific method for follow-up after treatment of Differentiated thyroid cancer is
- ARoentgenography
- BThyroglobulin
- CWhole-body scintigraphy with 131-Iodine
- DCorrect answers — b) and c)
23A Thyroid cancer presents on the conventional scintigram with 99mTc as
- AHot nodule
- BWarm nodule
- CCold nodule
- DAll answers are correct
24Which histologic types of Thyroid cancer COULD NOT be treated with 131-Iodine metabolic brachytherapy
- APapillary
- BFollicular
- CMedullary and anaplastic
- DCorrect answers — a) and b)
25An oncology patient referred for PET/CT should fast prior to the appointment for at least
- A12h
- B8h
- C4h
- D2h
26The recommended time interval for PET/CT. imaging after biopsy is
- A1 week
- B2-4 weeks
- C2-6 months
- Dmore than 6 months
27In order to avoid false-positive results, FDG PET/ CT scans should be performed
- A1-2 weeks after the last cycle of chemotherapy
- B2-4 weeks after the last cycle of chemotherapy
- C4-6 weeks after the last cycle of chemotherapy
- D6-8 weeks after the last cycle of chemotherapy
28False-negative PET/CT scans in lung cancer imaging occur predominantly because of
- ALesions are too big to be evaluated by PET
- BLesions are too superficial to be evaluated by PET
- CLesions are too small to be evaluated by PET
- DLesions are too deep to be evaluated by PET
29F-18 FDG PET/CT is considered as a superior modality, compared with CT for evaluating post-treatment response in lymphoma patients because of
- AThe ability to provide anatomical information
- BThe ability to differentiate viable tumour from fibrosis
- CHigher resolution
- DShorter imaging
30A breast-feeding patient referred for PET/CT imaging should
- ADiscontinue breast-feeding 12 h before injection of radiotracer
- BDiscontinue breast-feeding 6 h before injection of radiotracer
- CDiscontinue breast-feeding for at least 6 h after injection of radiotracer
- DDiscontinue breast-feeding for at least 12 h after injection of radiotracer
31A PET quantifier, calculated as the tracer activity concentration within a volume of interest divided by the injected dose per unit body weight is
- AFractional uptake value
- BStandardized upload value
- CStandardized uptake value
- DFractionai upload value
32The Standardized Uptake Value (SUV) is
- AThe measured activity divided by the body mass
- BThe amount of tracer needed for a particular body weight
- CThe measured activity normalized for body weight and inject dose
- DThe measured activity within a particular organ divided by the sampled volume
33For optimal patient care and interpretation of FDG PET/CT images, the following information from the patient should be obtained
- ABreast-feeding info
- BRecent surgery info
- CUse of medication info
- DAll answers are correct
34FDG PET/CT provides beneficial information in all of the following areas of lymphoma evaluation EXCEPT
- ADiagnosis
- BResponse to therapy
- CRecurrence detection
- DStaging
35Which of the following statements correctly explains the influence of FDG PET/CT imaging on staging in patients with Hodgkin's lymphoma
- AUpstaging of approximately 15-25 % of patients
- BDown-staging in a small minority of patients
- CUpstaging in a small minority of patients
- DDown-staging of approximately 15-25 % of patients
36All of the following are well-established indications for FDG PET/CT imaging in patients with recurrent colorectal carcinoma EXCEPT
- AFalling CEA levels in the absence of a known source
- BStaging recurrent colorectal carcinoma
- CPreoperative staging
- DEquivocal lesion on conventional imaging
37When monitoring response to treatment with FDG PET/CT Imaging is essential to obtain
- ABaseline FDG PET/CT scan
- BInterim FDG PET/CT scan
- CFDG PET/CT scan on the last day of therapy
- DFDG PET/CT scan two days after therapy
38FDG uptake by cancer cells tends to decline as
- ABlood glucose and insulin levels decrease
- BBlood glucose level decrease and insulin levels increase
- CBlood glucose and insulin levels increase
- DBlood glucose level increase and insulin levels decrease
39All of the following statements describe the usefulness of FDG PET/CT imaging in malignant pleural mesothelioma (MPM) EXCEPT
- AFDG PET/CT reduces the number of futile surgical procedures
- BFDG PET/CT imaging is useful for guiding needle biopsy
- CFDG PET/CT increases the accuracy of overall MPM staging
- DHigh levels of FDG uptake are associated with a favourable prognosis
40The intensity of FDG uptake in the majority of mesotheliomas
- ARanges from absent to low
- BRanges from low to moderate
- CRanges from moderate to high
- DIs always high
41Selected tumours with low FDG uptake include all of the following EXCEPT
- AProstate carcinoma
- BIodine-avid differentiated thyroid carcinoma
- CMetastatic liver carcinoma
- DHepatocellular carcinoma
42All of the following statements correctly describe the postsurgical 18-F FDG uptake at the intervention site EXCEPT
- APostsurgical 18-F FDG uptake is mainly diffuse
- BPostsurgical 18-F FDG uptake corresponds to the site of surgery
- CPostsurgical 18-F FDG uptake increases in intensity with time
- DPostsurgical 18-F FDG uptake in size with time
4318-F FDG PET/CT should be performed on patients previously treated for differentiated thyroid cancer when the finding of 131-I whole body scintigraphy are negative and
- AThe thyroglobuline (Tg) levels are more than 10 ng/ mL
- BThe thyroglobuline (Tg) levels are less than 10 ng/ mL
- CThe TSH levels are more than 30 mIU/L
- DThe TSH levels are less than 30 mIU/ L
44FDG PET/CT findings in anaplastic thyroid cancer can be described by all of the following EXCEPT
- AFDG PET/CT defines the local extent of disease and the presence of metastases
- BA positive PET/CT scan after therapy is linked with longer survival
- CFDG PET/CT have an impact on patients' management
- DIntense FDG uptake and volume are prognostic for a bad outcome
45FDG PET/CT used in patients with suspected and residual/ recurrent gliomas is limited by
- AThe low 18-F FDG uptake in normal brain tissue
- BThe high 18-F FDG uptake in normal brain tissue
- CThe low 18-F FDG uptake in tumour tissue
- DThe high 18-F FDG uptake in tumour tissue
4618-F FDG PET imaging is NOT indicated for initial staging of
- ABreast cancer
- BHodgkin's lymphoma
- CProstate cancer
- DLung cancer
47Which of the following statements describing 18-F FDG PET in the diagnostic work-up of patients with melanoma is FALSE
- AFDG PET is a standard modality in evaluation of recurrent melanoma
- BMelanin content influences lesion detectability by FDG PET
- CFDG PET is most valuable in stage III disease
- DFDG PET is more accurate for systemic staging than regional staging
48Ovarian uptake of 18-F FDG in a postmenopausal patient indicates
- AA normal finding
- BMalignancy
- CPregnancy
- DBenign ovarian cyst
49F-18 FDG focal uptake seen 6 months after completion of radiation therapy should be considered as
- ATumour recurrence
- BNormal finding
- CRadiation necrosis
- DRadiation pneumonitis
50According to the PERCIST (PET Response Criteria in Solid Tumours) criteria for treatment response evaluation, the changes in SUVs should be assessed as
- APercentage change in the same lesion
- BPercentage change in the “hottest” lesion
- CValue change in the same lesion
- DValue change in the “hottest” lesion
Information
- Description
- Test of Nuclear Medicine- Oncology 5th Year PMU
- Author
- Med Student
- Language
- English
- Views
- 2,160
- Tags
- Rating
- 5.0 out of 5 · 1 rating Rate this quiz